Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis
Status:
Completed
Trial end date:
2018-04-10
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of abrilumab on induction of
remission in adults with moderate to severe ulcerative colitis after 8 weeks of treatment as
assessed by a total Mayo Score ≤ 2 points, with no individual subscore > 1 point.